Like the proverbial wolf in sheep's clothing, B cells can hide the fact that they are harboring a dangerous autoreactive immunoglobulin (Ig) by displaying a second innocuous Ig. Casellas et al. (page 153) now reveal how these fluffy white villains come to exist and, rather worryingly, that there are potentially large numbers of them in our system. Transgenic B cells forced to express one selfreactive Ig allele can switch on a second nonautoreative Ig in a process called allelic inclusion. This second Ig appears to dilute the autoreactive potential of the cell. But it is unknown whether allelic inclusion, which defies the "one lymphocyte-one antibody" theory of B cell specificity, can occur under normal physiological conditions.
Using physiologically normal mice that carried one human and one endogenous allele of the Ig light chain gene (to enable identification of both), Casellas et al. discovered that approximately 10% of B cells express two Ig light chain alleles.
The coexpressing cells might arise either because allelic exclusion-the permanent switching-off of one allele-fails or because the second allele gets switched on during receptor editing. Such editing, which occurs if the first Ig produced by a B cell is discovered to be autoreactive, involves switching back on the machinery necessary for Ig gene recombination and expression. With this machinery back on, the second allele might get activated.
Consistent with this hypothesis, coexpression and autoreactivity were correlated. The team also sequenced the Ig genes in coexpressing cells and found strong evidence that editing had occurred. The developmental path of these coexpressing cells was slower than that of monoexpressing cells, consistent with a necessary pause for editing.
The coexpressing B cells, though large in number, appear to have their autoreactive tendencies tempered by the second Ig allele. However, B cells undergo somatic hypermutation at their Ig genes during an immune response, suggesting that autoimmune disease might be triggered if the innocuous allele is edited into oblivion and the wolf is let loose.
Cell replacement therapy-are MAPCs the answer?
Inherited blood disorders could be a thing of the past. Serafini et al. report on page 129 that multipotent adult progenitor cells (MAPCs), produced in vitro from bone marrow, have blood-building capacity in immune-deficient mice.
The full complement of blood cell types arises from hematopoietic stem cells (HSCs) of the bone marrow. The ability of these cells to both self-renew and to produce daughter cells capable of any hematopoietic fate makes them an attractive resource for cell replacement therapy for blood and immune disorders. However, as with adult stem cells from other tissues, long-term culturing of these cells has proven difficult.
MAPCs, on the other hand, can divide seemingly endlessly in culture. These cells, which can give rise to multiple cell types, were discovered by chance when Catherine Verfaillie's group was trying to culture another type of adult stem cell. The group now shows that MAPCs can reconstitute hematopoietic compartments in vivo just as well as HSCs. Indeed they can even give rise to HSCs themselves.
The team irradiated mice to knock out their immune cells and then injected traceable MAPCs. MAPC-derived cells were detectable in the bone marrow, spleen, peripheral blood, and lymph nodes of recipient mice and expressed appropriate B, T, and myeloid cell surface markers. Furthermore, MAPC-derived B and T cells were shown to be functional by their production of immunoglobulin and response to T cell receptor stimulus, respectively. The team showed that MAPCs also gave rise to functional long-term HSCs. Transfer of bone marrow cells from the primary recipient mice into new irradiated mice once again led to hematopoietic reconstitution, as did a third round of transfer from these secondary mice to tertiary recipients.
None of the recipient mice in the study developed tumors, even though some of the MAPCs they received were genetically abnormal because of long-term culturing. Genotyping of the recipients' peripheral blood revealed normal karyotypes, leading Verfaillie to suggest that the genetically abnormal MAPCs were somehow cleared by the body.
The risk of tumor development from transplanted embryonic stem cells (ESCs) is an ongoing concern for their use in therapy. The potential of long-term culture followed by tumor-free cell transfer thus gives MAPCs a therapeutic advantage over both ESCs and HSCs.
MAPC-derived cells (green) restock the lymph nodes of an immunocompromised mouse.

The secret autoreactivity of B cells
A surprisingly large number of B cells express two different Ig light chain alleles (red and green).
